AU2004296206A1 - Treatment and preventions of asthma - Google Patents

Treatment and preventions of asthma Download PDF

Info

Publication number
AU2004296206A1
AU2004296206A1 AU2004296206A AU2004296206A AU2004296206A1 AU 2004296206 A1 AU2004296206 A1 AU 2004296206A1 AU 2004296206 A AU2004296206 A AU 2004296206A AU 2004296206 A AU2004296206 A AU 2004296206A AU 2004296206 A1 AU2004296206 A1 AU 2004296206A1
Authority
AU
Australia
Prior art keywords
composition
seq
phosphatidylcholine
amino acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004296206A
Other languages
English (en)
Inventor
Charles G. Cochrane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2004296206A1 publication Critical patent/AU2004296206A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2004296206A 2003-12-04 2004-12-03 Treatment and preventions of asthma Abandoned AU2004296206A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52678703P 2003-12-04 2003-12-04
US60/526,787 2003-12-04
PCT/US2004/040665 WO2005055994A1 (en) 2003-12-04 2004-12-03 Treatment and preventions of asthma

Publications (1)

Publication Number Publication Date
AU2004296206A1 true AU2004296206A1 (en) 2005-06-23

Family

ID=34676656

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004296206A Abandoned AU2004296206A1 (en) 2003-12-04 2004-12-03 Treatment and preventions of asthma

Country Status (6)

Country Link
US (1) US20070129297A1 (enExample)
EP (1) EP1694314A4 (enExample)
JP (1) JP2007513180A (enExample)
AU (1) AU2004296206A1 (enExample)
CA (1) CA2549160A1 (enExample)
WO (1) WO2005055994A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005306619B2 (en) * 2004-11-15 2011-11-03 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
WO2005073246A2 (en) * 2004-01-20 2005-08-11 Discovery Laboratories, Inc. Method for preparing kl4 lung surfactant
JPWO2007001094A1 (ja) * 2005-06-29 2009-01-22 相男 李 人工肺サーファクタント組成物
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
EP2035010B1 (en) * 2006-06-09 2012-10-03 Erasmus University Medical Center Rotterdam Modulation of the immune system by inositol phospholipids
EP2063903A1 (en) * 2006-09-19 2009-06-03 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
EP2170270B1 (en) * 2007-06-05 2016-01-13 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
CA2707986A1 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
JP5801206B2 (ja) 2009-01-30 2015-10-28 アルファベータ・エービーＡｌｐｈａＢｅｔａ ＡＢ アルツハイマー病の治療のための化合物および方法
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia
JP6227523B2 (ja) 2011-04-05 2017-11-08 アルファベータ・エービーＡｌｐｈａＢｅｔａ ＡＢ 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット
WO2013081452A1 (en) 2011-11-30 2013-06-06 Erasmus University Medical Center Rotterdam Phosphatidylinositol
US20210379141A1 (en) * 2016-04-11 2021-12-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
WO2017180546A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
JP2024505225A (ja) * 2021-01-29 2024-02-05 サインパス ファルマ，インク． 肺損傷を減少させ、肺機能を改善し、炎症促進性サイトカインを低下させる脂質

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US6613734B2 (en) * 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5301644A (en) * 1993-06-16 1994-04-12 Kohler Co. Fuel shut-off mechanism for internal combustion engines
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5878912A (en) * 1995-12-26 1999-03-09 Stein; Myron Duct disinfecting method and apparatus
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US6051257A (en) * 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
US5973574A (en) * 1997-04-21 1999-10-26 Eastman Kodak Company Oscillator system with corrective frequency modulation
US5833084A (en) * 1997-07-18 1998-11-10 Chang; Hsi-Te Modular rack
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
WO2000027360A1 (en) * 1998-11-10 2000-05-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Treatment set containing lungsurfactant compositions
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005306619B2 (en) * 2004-11-15 2011-11-03 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof

Also Published As

Publication number Publication date
JP2007513180A (ja) 2007-05-24
EP1694314A4 (en) 2009-07-01
EP1694314A1 (en) 2006-08-30
WO2005055994A1 (en) 2005-06-23
US20070129297A1 (en) 2007-06-07
CA2549160A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
US7863241B2 (en) Compositions for treatment and prevention of pulmonary conditions
US20070129297A1 (en) Treatment and prevention of asthma
EP1833503B1 (en) Pulmonary surfactant formulations
JP2005529885A5 (enExample)
JP2013177422A (ja) サーファクタント処置療法
WO2007005672A2 (en) Treatment and prevention of respiratory diseases and conditions
RU2748417C2 (ru) Стабильная фармацевтическая композиция, включающая восстановленную композицию легочного сурфактанта
WO2015061412A1 (en) Methods and compositions for promoting bronchioli dilatation
HK1109077B (en) Pulmonary surfactant formulations
HK1134497B (en) Reconstituted surfactants having improved properties
HK1134497A1 (en) Reconstituted surfactants having improved properties

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application